Nextplat Corp (NXPL) - Q2 2026 10-Q Summary
Business Context and Reporting Period
This summary covers the quarterly period ended June 30, 2026. Nextplat Corp operates two primary segments: e-Commerce Operations (satellite communication equipment and services) and Healthcare Operations (pharmacy services, 340B contract pharmacy, and healthcare data analytics). The company is a non-accelerated filer and smaller reporting company listed on the Nasdaq Capital Market.
Key Financial Metrics
| Metric | Q2 2026 (3 Months) | Q2 2025 (3 Months) | YTD 2026 (6 Months) | YTD 2025 (6 Months) |
|---|---|---|---|---|
| Net Revenue | $11.9 million | $13.2 million | $21.7 million | $27.2 million |
| Gross Profit | $4.7 million | $2.9 million | $8.1 million | $5.7 million |
| Gross Margin | 39.5% | 21.8% | 37.3% | 21.2% |
| Operating Loss | $(0.1 million) | $(1.8 million) | $(1.2 million) | $(3.9 million) |
| Net Loss (Common) | $(0.1 million) | $(1.8 million) | $(1.3 million) | $(3.7 million) |
| EPS (Basic/Diluted) | $(0.05) | $(0.69) | $(0.47) | $(1.44) |
| Cash & Equivalents | $11.9 million (as of June 30, 2026) | |||
| Working Capital | $14.2 million (as of June 30, 2026) | |||
| Total Debt | $1.0 million (Notes Payable) |
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased 10% QoQ and 20% YTD compared to 2025. This was driven primarily by a significant drop in Healthcare prescription revenue due to lower reimbursement rates and reduced volume.
- Margin Expansion: Despite lower revenue, gross margin improved significantly from ~22% to ~40% (Q2) and ~21% to ~37% (YTD). This was driven by a shift in the Healthcare mix toward higher-margin 340B contract pharmacy services and the implementation of the Medicare Maximum Fair Price program.
- Loss Reduction: Operating loss narrowed by 93% in Q2 and 69% YTD compared to the prior year, reflecting improved gross profitability and reduced operating expenses (specifically salaries and depreciation).
- Cost Management: Operating expenses remained relatively flat QoQ but decreased YTD. Salaries and wages decreased due to headcount reductions and lower executive compensation, partially offset by higher professional fees.
Outlook, Risks, and Unusual Items
- Going Concern: Management previously raised substantial doubt about the company's ability to continue as a going concern. However, based on reduced operating losses, improved cash flow, and available liquidity ($11.9M cash + $3.8M ATM program), management now believes this doubt is alleviated.
- ATM Program: An At-The-Market offering program was established in May 2026 with up to $3.8 million in capacity. No shares have been sold as of the filing date.
- Subsequent Events:
- Acquisition: Entered an agreement on July 14, 2026, to acquire Scott's Pharmacy, LLC for $1.5 million cash.
- Lease: Signed a new 5-year lease for a pharmacy location in Jacksonville, FL, commencing August 1, 2026.
- Legal Contingency: A putative class action lawsuit regarding the 2024 RXMD merger remains pending. The company has accrued $1.75 million for this matter, representing its insurance retention.
- Internal Controls: Material weaknesses in internal controls regarding PBM performance bonus estimates and PIPE warrant valuation remain unremediated as of June 30, 2026, though remediation plans are in progress.
Investor Verification Checklist
- Revenue Quality: Verify the sustainability of the gross margin expansion given the 20% decline in total revenue and the heavy reliance on 340B contract pharmacy revenue.
- Liquidity Runway: Confirm the company's ability to fund the $1.5M pharmacy acquisition and ongoing operations without immediate equity dilution, given the history of negative operating cash flows.
- Legal Exposure: Monitor the status of the Weisberg v. NextPlat litigation to ensure the $1.75M accrual remains sufficient and does not escalate.
- Internal Controls: Track the remediation progress of the identified material weaknesses in financial reporting, specifically regarding revenue recognition estimates.
- Supplier Concentration: Note that 99% of Healthcare vendor purchases are from McKesson and 30% of e-Commerce purchases are from Iridium Satellite, creating significant supply chain concentration risk.